Opinion|Videos|May 1, 2024
New Therapeutic Frontiers in PAH
Author(s)Ronald Oudiz, MD, FACP, FACC, FCCP
A cardiovascular specialist provides an overview of emerging therapies and targets in the PAH treatment space and how they address current unmet needs.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What new therapeutic options have emerged in the pulmonary arterial hypertension (PAH) treatment landscape, and what are their mechanisms of action and potential benefits?
- How do emerging therapies address the unmet needs in PAH management, such as improving symptom control, slowing disease progression, or targeting specific pathways?
Advertisement
Related to this article
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
The EEOC is reportedly preparing to narrow Pregnant Workers Fairness Act rules; no revised rule has been published as of yet.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Pooled data on 2698 patients tie rituximab maintenance after bendamustine-rituximab to better PFS and OS in mantle cell lymphoma.
Among 788 patch-tested patients with hand eczema in Shanghai, 82% reacted to at least 1 allergen.
The Community Oncology Alliance said final 2027 Medicare payment rules address longstanding gaps between hospital and community practice reimbursement, but it urged Congress to stop another physician pay cut and to fix how the Inflation Reduction Act will pay practices for Part B drugs.
Gerald Criner, MD, outlines which patients with advanced COPD may need oxygen, home NIV, or high-flow therapy and when to discuss goals of care.
Advertisement
Advertisement
Trending on AJMC
1
NYC Marathon Death Puts Rhabdomyolysis Risk Factors in Focus
2
Real-World Evidence, Rare Liver Disease Data Headline Kidney Week 2026
3
Acoramidis Linked to Fewer Hospitalizations Than Tafamidis in ATTR-CM
4
Disease Extent Linked to Complications After Deep Endometriosis Surgery
5